Enzymatic Revolution | Codexis pivots to RNAi therapeutics manufacturing, leveraging its ECO Synthesis platform to address critical challenges in drug production scalability and efficiency |
Market Opportunity | Explore the billion-dollar potential in the growing RNAi therapeutics market, where Codexis aims to revolutionize manufacturing processes with its innovative approach |
Financial Fortitude | Delve into Codexis's robust financial position, with $90.3 million in cash reserves providing runway until 2027, despite current negative EBITDA of -$45.78 million |
Analyst Outlook | Cantor Fitzgerald maintains a consistent $11.00 price target throughout 2024, reflecting cautious optimism about Codexis's potential in the RNAi manufacturing arena |
Metrics to compare | CDXS | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipCDXSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.4x | −3.9x | −0.5x | |
PEG Ratio | −0.12 | −0.01 | 0.00 | |
Price/Book | 5.5x | 1.7x | 2.6x | |
Price / LTM Sales | 3.0x | 5.6x | 3.1x | |
Upside (Analyst Target) | 171.2% | 128.3% | 53.2% | |
Fair Value Upside | Unlock | 2.1% | 6.2% | Unlock |